Loading...
01/10 16:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects mixed signals. Basic financial performance shows slight improvement in adjusted EBITDA net loss, but there's a delay in profitability. Product development is active, but with uncertainties in TAC-STIM and international revenue. Market strategy is cautious, with some success in VA channels. Expenses are increasing, impacting financial health. Shareholder returns are not addressed. Q&A reveals cautious expansion and litigation issues. Overall, the stock price reaction is likely neutral due to balanced positive and negative elements.
Revenue Revenue reached a record $8.7 million in Q3 2025, up 33% year-over-year and 18% sequentially. This growth was driven by higher sales of prescription devices and growth in the company's non-prescription general wellness Truvaga product.
Gross Margin Gross margins remained strong at 86%, up slightly from 84% last year. This improvement reflects operational efficiencies and product mix.
Prescription Device Revenue Prescription device revenue grew 19% year-over-year to $6.8 million, driven by both gammaCore and Quell sales in the VA hospital system. The increase is attributed to expanded adoption and sales efforts.
Health and Wellness Product Revenue Health and wellness product revenue reached $1.9 million, a 54% increase sequentially and 121% year-on-year. This includes a $500,000 onetime Truvaga order for a third-party clinical trial. Excluding that, Truvaga revenue grew 18% sequentially and 79% year-on-year, driven by a shift away from Amazon and increased focus on direct-to-consumer platforms.
Operating Expenses Total operating expenses in Q3 2025 were approximately $10.4 million, up from $8.1 million in Q3 2024. The increase was primarily due to greater investment in selling and marketing costs, consistent with the company's increase in sales.
Net Loss GAAP net loss in Q3 2025 was $3.4 million, compared to a net loss of $2.5 million in Q3 2024. The increase in net loss is attributed to an increase in other expenses related to the CVR liability and interest expense on convertible debt financing.
Adjusted EBITDA Net Loss Adjusted EBITDA net loss in Q3 2025 was $2 million, compared to $2.1 million in Q3 2024. This slight improvement reflects operational efficiencies despite increased investments.
Cash Balance Cash balance as of September 30, 2025, was $13.2 million, up from $12.2 million as of December 31, 2024. The increase is due to securing a term debt facility and a private placement.
Truvaga: Sales returned to growth, driven by e-commerce and affiliate networks. Revenue reached $1.9 million, a 54% sequential increase and 121% year-on-year. Truvaga has sold over 19,000 handsets, powering 1.6 million user sessions on its mobile app.
Quell Fibromyalgia: Acquired from NeuroMetrix and launched in July 2025. Early performance exceeded expectations, with third and fourth quarter results projected to cover acquisition costs and support future revenue growth.
gammaCore: Prescription device sales grew 19% year-over-year to $6.8 million, driven by VA hospital system adoption. 12,000 devices dispensed, addressing 2% of the VA headache market.
VA hospital system: Secured a new 5-year contract, upgraded from a 3-year agreement. Expanded sales team and strategies to boost adoption. VA revenue growth resumed after a temporary slowdown.
China market: Broadened options outside the U.S. through a royalty-based arrangement with a China-based investor. No capital investment required from electroCore.
Managed care systems: Finalized a contract providing access and coverage for therapies. Modest investment in a dedicated sales team to create sustained revenue streams.
Revenue growth: Third quarter revenue reached $8.7 million, up 33% year-over-year and 18% sequentially. Gross margins remained strong at 86%.
Strategic investments: Invested in sales, marketing, and product development to accelerate growth. Added new Board members and partnered with AI firm StratejAI to enhance wellness app.
NeuroMetrix acquisition: Acquired Quell portfolio, diversifying offerings and mitigating product risk. Added FDA-cleared Quell Fibromyalgia and Quell Relief brands.
AI and software integration: Partnered with StratejAI to develop personalized, data-driven user experiences for wellness products, aiming to establish recurring revenue streams.
International expansion: Focused on EU, Middle East, and China markets through strategic partnerships and Board expertise.
Profitability Delays: The company has chosen to delay profitability until the second half of 2026 to prioritize growth and long-term value creation. This decision involves increased operating expenses and investments in marketing, sales, and product development, which could strain cash flow and financial stability in the short term.
Regulatory and Commercialization Risks: The company's expansion into international markets, including China, depends on local regulatory processes and commercialization efforts by third parties. Delays or failures in these processes could impact revenue growth and market penetration.
Patent Infringement Dispute: A potential patent and trademark infringement by a Truvaga copycat from Eastern Europe has led to legal action. This ongoing dispute could result in financial and reputational risks.
Customer Concentration Risk: The VA hospital system remains the largest customer, accounting for a significant portion of revenue. Over-reliance on this channel poses a risk if demand fluctuates or external factors impact this relationship.
Macroeconomic and Political Factors: The company experienced a temporary slowdown in VA revenue growth in Q4 2024 due to external macroeconomic and political factors. Similar disruptions could occur in the future, affecting revenue stability.
Increased Operating Expenses: Operating expenses have risen due to investments in sales, marketing, and product development. This could pressure margins and delay the path to profitability if revenue growth does not meet expectations.
Competition and Market Dynamics: The company faces competition in the noninvasive vagus nerve stimulation market and the broader wellness market. Failure to differentiate its products or respond to competitive pressures could impact market share and revenue.
Cash Flow Management: The company forecasts using approximately $5 million in cash to fund operations in the first nine months of 2026. Any deviation from revenue projections could lead to liquidity challenges.
Revenue Guidance: The company is increasing full-year 2025 revenue guidance to $31.5 million to $32.5 million.
Profitability Timeline: The company expects to achieve positive adjusted EBITDA in the second half of 2026, with quarterly revenue reaching approximately $12 million.
Cash Balance: The company forecasts a cash balance of approximately $10.5 million as of December 31, 2025.
Growth Investments: Investments are being made in people, marketing, and product development to accelerate growth and scale in 2026 and 2027.
VA Hospital Channel Expansion: The company plans to add W-2 and 1099 staff in select locations through 2026 to grow the VA hospital business.
Managed Care System Growth: The company is investing in sales talent to focus on a large commercial managed care system, with gammaCore Sapphire added to a managed care system contract.
Health and Wellness Division: The company is developing new health and wellness offerings, including Quell Relief for lower extremity pain, and enhancing its Truvaga platform with marketing and promotional investments.
AI and Software Integration: Development of next-generation applications to complement Truvaga and Quell is underway, aiming to create personalized data-driven user experiences and new recurring revenue streams.
International Expansion: The company is broadening its opportunities outside the U.S. through a royalty-based arrangement in China and leveraging connections in the EU and Middle East for expansion.
The selected topic was not discussed during the call.
The earnings call reflects mixed signals. Basic financial performance shows slight improvement in adjusted EBITDA net loss, but there's a delay in profitability. Product development is active, but with uncertainties in TAC-STIM and international revenue. Market strategy is cautious, with some success in VA channels. Expenses are increasing, impacting financial health. Shareholder returns are not addressed. Q&A reveals cautious expansion and litigation issues. Overall, the stock price reaction is likely neutral due to balanced positive and negative elements.
The earnings call presents mixed signals. The VA revenue growth and Truvaga's year-over-year sales increase are positives. However, the sequential decline in Truvaga sales, increased operating expenses, and net loss raise concerns. The Q&A highlights uncertainties around patent litigation and unclear marketing spend impacts. While new product lines and integrations offer potential, the lack of specific guidance and profitability delays temper optimism. Given these factors, the stock price reaction is likely to remain neutral.
The earnings call reveals mixed signals: strong revenue growth and gross margins, yet a significant cash burn and lack of 2025 guidance. The acquisition of NeuroMetrix adds complexity, while market access risks and operational challenges persist. The Q&A session highlighted management's lack of clarity on margin estimates and revenue growth projections, which could concern investors. Despite positive developments like the Truvaga expansion and distribution agreement, the absence of a shareholder return plan and cash flow risks temper optimism, leading to a neutral stock price prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
